Levosimendan treatment after primary organ failure in heart transplantation: A direct way to recovery?

Transplantation

Volumn 82, Issue 8, 2006, Pages 1101-1103

  Beiras Fernandez, Andres ^a   Weis, Florian C ^a   Fuchs, Herbert ^a   Meiser, Bruno M ^a   Reichart, Bruno ^a   Weis, Marion ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Heart failure; Ischemia; Levosimendan; Primary organ failure; Transplantation

Indexed keywords

ADRENALIN; LEVOSIMENDAN; MILRINONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; PROSTAGLANDIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; AGED; ARTICLE; CASE REPORT; FEMALE; HEART EJECTION FRACTION; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ADOLESCENT; AGED; CALCIUM; CARDIOMYOPATHIES; CATECHOLAMINES; FEMALE; HEART; HEART TRANSPLANTATION; HUMANS; HYDRAZONES; ISCHEMIA; MALE; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES;

EID: 33750355697     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000233845.15508.89     Document Type: Article

References (13)

1. Mitropoulos FA, Odim J, Marelli D, et al. Outcome of hearts with cold ischemic time greater than 300 minutes. A case-matched study. Eur J Cardiothorac Surg 2005; 28(1): 143.
2. Deng MC, Edwards LB, Hertz MI, et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report - 2005. J Heart Lung Transplant 2005; 24(9): 1182.
3. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196.
4. Brixius K, Hoyer HK, Schwinger RH. Ca (2+)-sensitisers-a promising option to treat heart failure? Cardiovasc Drugs Ther 2005; 19(6): 423.
5. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422.
6. Ellger BM, Zahn PK, Van Aken HK, et al. Levosimendan: a promising treatment for myocardial stunning? Anaesthesia 2006; 61(1): 61.
7. Schulze-Neick I, Luther YC, Ewert P, et al. End-stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart-lung transplantation. Transplantation 2004; 78(8): 1237.
8. Jahania MS, Mullett TW, Sanchez JA, et al. Acute allograft failure in thoracic organ transplantation. J Card Surg 2000; 15(2): 122.
9. Laks H, Marelli D, Fazio D, Kobashigawa JA. Expanding the heart donor base. Curr Opin Organ Transplant 2000; 5: 134.
10. Szabo G, Sebening C, Hackert T, et al. Influence of brain death and cardiac preservation on systolic and diastolic function and coronary circulation in the cross-circulated canine heart. World J Surg 1999; 23(1): 36.
11. Tisdale JE, Patel R, Webb CR, et al. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995; 38(2): 167.
12. Lietz K, Miller LW. Will left-ventricular assist device therapy replace heart transplantation in the foreseeable future? Curr Opin Cardiol 2005; 20(2): 132.
13. Toller WG, Stranz C. Levosimendan, a New Inotropic and Vasodilator Agent. Anesthesiology 2006; 104(3): 556.